Analysts expect BIONDVAX PHARMA/S (NASDAQ:BVXV) to post ($0.02) earnings per share (EPS) for the current quarter, according to Zacks. Zero analysts have issued estimates for BIONDVAX PHARMA/S’s earnings. BIONDVAX PHARMA/S reported earnings of ($1.12) per share during the same quarter last year, which would indicate a positive year-over-year growth rate of 98.2%. The firm is expected to report its next quarterly earnings results on Wednesday, August 28th.

According to Zacks, analysts expect that BIONDVAX PHARMA/S will report full-year earnings of ($0.08) per share for the current year. For the next financial year, analysts expect that the company will report earnings of ($0.07) per share. Zacks Investment Research’s earnings per share averages are an average based on a survey of analysts that follow BIONDVAX PHARMA/S.

BIONDVAX PHARMA/S (NASDAQ:BVXV) last issued its earnings results on Thursday, May 30th. The company reported $0.02 EPS for the quarter.

Separately, ValuEngine lowered Zumiez from a “hold” rating to a “sell” rating in a research report on Tuesday, July 2nd.

NASDAQ BVXV traded up $0.05 during trading hours on Friday, reaching $5.85. The stock had a trading volume of 100 shares, compared to its average volume of 3,270. The company’s fifty day moving average is $6.08. The stock has a market cap of $39.12 million, a PE ratio of -1.66 and a beta of 1.11. BIONDVAX PHARMA/S has a 52-week low of $3.51 and a 52-week high of $7.26.


BiondVax Pharmaceuticals Ltd., a clinical stage biopharmaceutical company, focuses on developing and commercializing immunomodulation therapies for infectious diseases primarily in Israel. Its product candidate is M-001, a synthetic peptide-based protein, which has completed Phase II clinical trials that is used for treating seasonal and pandemic strains of the influenza virus.

See Also: Market Perform

Get a free copy of the Zacks research report on BIONDVAX PHARMA/S (BVXV)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for BIONDVAX PHARMA/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIONDVAX PHARMA/S and related companies with's FREE daily email newsletter.